ArticleEuropean radiology2024
Gadolinium-enhanced intracranial aneurysm wall imaging and risk of aneurysm growth and rupture: a multicentre longitudinal cohort study.
Article in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Association of hypertension and blood pressure control with aneurysm wall enhancement in unruptured intracranial aneurysms: a multicenter propensity score-matched study.European radiology · 2026Observational
- Local pressure as a dominant hemodynamic driver of wall enhancement in anterior communicating artery aneurysms: a facet-level computational fluid dynamics and vessel wall imaging analysis.Quantitative imaging in medicine and surgery · 2026Article
- Aneurysm Wall Enhancement in Patients With Unruptured Intracranial Aneurysm Using Aspirin or Statins: A Cross-Sectional Analysis of Three Prospective Cohorts.AJNR. American journal of neuroradiology · 2026Article
- Aneurysm Wall Enhancement and Probability of Instability in Unruptured Intracranial Aneurysms: A Long-Term Follow-Up Study.Annals of neurology · 2026Article
- Novel VSMC-associated biomarkers in intracranial aneurysm pathogenesis: a multi-omics and machine learning study.BMC neurology · 2026Article
- Analysis of symptomatic brain aneurysms with three-dimensional aneurysm wall enhancement.Neurosurgical review · 2026Observational
- From hemodynamic stress to inflammatory wall remodeling in intracranial aneurysms.Frontiers in molecular biosciences · 2026Review
- Appearance and Disappearance of Intracranial Aneurysm Wall Enhancement during Follow-Up: A Multicenter Cohort Study.AJNR. American journal of neuroradiology · 2025Article
- Mechanisms of Intracranial Aneurysm Rupture: An Integrative Review of Experimental and Clinical Evidence.Journal of clinical medicine · 2025Review
- Triglyceride-Glucose Index Predicts Instability in the Natural History of Intracranial Aneurysms: Insights From a Large-Scale Chinese Multicenter Cohort.Journal of the American Heart Association · 2025Article
- Radiomics-Based Predictive Nomogram for Assessing the Risk of Intracranial Aneurysms.Translational stroke research · 2025Article
- Aneurysm Wall Enhancement and Systemic Inflammation Jointly Contribute to Cognitive Dysfunction in Untreated Unruptured Intracranial Aneurysm Patients.Journal of inflammation research · 2025Article
- Intra-Aneurysmal High-Resolution 4D MR Flow Imaging for Hemodynamic Imaging Markers in Intracranial Aneurysm Instability.AJNR. American journal of neuroradiology · 2024Article
- Radiomics-Based Predictive Nomogram for Assessing the Risk of Intracranial Aneurysms.Research square · 2024Article
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Funding
Abstract
objectivesIn patients with an unruptured intracranial aneurysm, gadolinium enhancement of the aneurysm wall is associated with growth and rupture. However, most previous studies did not have a longitudinal design and did not adjust for aneurysm size, which is the main predictor of aneurysm instability and the most important determinant of wall enhancement. We investigated whether aneurysm wall enhancement predicts aneurysm growth and rupture during follow-up and whether the predictive value was independent of aneurysm size. MATERIALS AND
methodsIn this multicentre longitudinal cohort study, individual patient data were obtained from twelve international cohorts. Inclusion criteria were as follows: 18 years or older with ≥ 1 untreated unruptured intracranial aneurysm < 15 mm; gadolinium-enhanced aneurysm wall imaging and MRA at baseline; and MRA or rupture during follow-up. Patients were included between November 2012 and November 2019. We calculated crude hazard ratios with 95%CI of aneurysm wall enhancement for growth (≥ 1 mm increase) or rupture and adjusted for aneurysm size.
resultsIn 455 patients (mean age (SD), 60 (13) years; 323 (71%) women) with 559 aneurysms, growth or rupture occurred in 13/194 (6.7%) aneurysms with wall enhancement and in 9/365 (2.5%) aneurysms without enhancement (crude hazard ratio 3.1 [95%CI: 1.3-7.4], adjusted hazard ratio 1.4 [95%CI: 0.5-3.7]) with a median follow-up duration of 1.2 years.
conclusionsGadolinium enhancement of the aneurysm wall predicts aneurysm growth or rupture during short-term follow-up, but not independent of aneurysm size. CLINICAL RELEVANCE STATEMENT: Gadolinium-enhanced aneurysm wall imaging is not recommended for short-term prediction of growth and rupture, since it appears to have no additional value to conventional predictors. KEY POINTS: • Although aneurysm wall enhancement is associated with aneurysm instability in cross-sectional studies, it remains unknown whether it predicts risk of aneurysm growth or rupture in longitudinal studies. • Gadolinium enhancement of the aneurysm wall predicts aneurysm growth or rupture during short-term follow-up, but not when adjusting for aneurysm size. • While gadolinium-enhanced aneurysm wall imaging is not recommended for short-term prediction of growth and rupture, it may hold potential for aneurysms smaller than 7 mm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.